2016 ASCO Annual Meeting Abstract 8059: Healthcare Costs Among Multiple Myeloma (MM) Patients (Pts) Without Stem Cell Transplant (SCT)
MM Tx medications and tx of MM complications/AEs represent the majority of healthcare costs in MM pts. Monthly MM Tx medication costs were greatest for 4L+ and monthly total costs at treatment initiation were greatest for 1L. In each LOT monthly costs declined over time. Therapies that extend PFS and the treatment-free interval may reduce the costs of MM treatment and likely defer costs of subsequent MM tx.
ASCO
In The News
American Society of Hematology 2016 Annual Meeting
Session 731. Clinical Autologous Transplantation: Results: Clinical Autologous Transplantation in Myeloma I
American Society of Hematology 2016 Annual Meeting
Session 653. Myeloma: Therapy, excluding Transplantation: IMiD/Proteasome Inhibitor Combinations and Maintenance Therapy
American Society of Hematology 2016 Annual Meeting
Abstract 1143: Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study
American Society of Hematology 2016 Annual Meeting
Abstract 673: Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial)
In The Literature
Bone Marrow Transplant